Skip to main content
Fig. 3 | Journal of Ovarian Research

Fig. 3

From: Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells

Fig. 3

In vitro induction of apoptosis in HOACs by Dasatinib, Gefitinib or a combination of both drugs. The Dasatinib and Gefitinib synergic effect does not imply apoptosis induction. HOACs were treated with Dasatinib, Gefitinib (IC50 after 72 h of treatment for each cell line) or an equieffective combination of both treatments. The negative control corresponds to non-treated cells. Forty-eight hours after treatment, cells were stained with a FITC-Annexin V/PI apoptosis detection kit. Early apoptotic cells correspond to the Annexin V positive and PI negative population. (Mean +/− SEM, ** = p < 0.01, *** = p < 0.001 n = 3)

Back to article page